SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 1256-1264. Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-06-2416. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-06-2416v1 105/3/1256    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Garnache-Ottou, F. Articles by Saas, P. Search for Related Content PubMed PubMed Citation Articles by Garnache-Ottou, F. Articles by Saas, P. Related Collections Gene Expression Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells Francine Garnache-Ottou, Laurence Chaperot, Sabeha Biichle, Christophe Ferrand, Jean-Paul Remy-Martin, Eric Deconinck, Patrick Darodes de Tailly, Bénédicte Bulabois, Jacqueline Poulet, Emilienne Kuhlein, Marie-Christine Jacob, Véronique Salaun, Michel Arock, Bernard Drenou, Françoise Schillinger, Estelle Seilles, Pierre Tiberghien, Jean-Claude Bensa, Joel Plumas, and Philippe Saas From the Etablissement Français du Sang Bourgogne Franche-Comté, Unité mixte EFS/Université EA2284/Inserm U645, IFR133, Besançon, France; Etablissement Français du Sang Rhône-Alpes, Grenoble, France; Service d'Hématologie, CHU Jean Minjoz, Besançon, France; Service d'Immunologie, CHU Rangueil, Toulouse, France; Laboratoire d'Hématologie, CHU Côte de Nacre, Caen, France; Cellular and Molecular Hematology, CNRS FRE 2444, Faculty of Pharmacy, Paris, France; Laboratoire d'Hématologie, CHU Pontchaillou, Rennes, France. A new entity of acute leukemia coexpressing CD4+CD56+ markers without any other lineage-specific markers has been identified recently as arising from lymphoid-related plasmacytoid dendritic cells (pDCs). In our laboratory, cells from a patient with such CD4+CD56+ lineage-negative leukemia were unexpectedly found to also express the myeloid marker CD33. To confirm the diagnosis of pDC leukemia despite the CD33 expression, we demonstrated that the leukemic cells indeed exhibited pDC phenotypic and functional properties. In 7 of 8 other patients with CD4+CD56+ pDC malignancies, we were able to confirm that the tumor cells expressed CD33 although with variable expression levels. CD33 expression was shown by flow cytometry, reverse transcriptase-polymerase chain reaction, and immunoblot analysis. Furthermore, CD33 monoclonal antibody stimulation of purified CD4+CD56+ leukemic cells led to cytokine secretion, thus confirming the presence of a functional CD33 on these leukemic cells. Moreover, we found that circulating pDCs in healthy individuals also weakly express CD33. Overall, our results demonstrate that the expression of CD33 on CD4+CD56+ lineage-negative cells should not exclude the diagnosis of pDC leukemia and underline that pDC-specific markers should be used at diagnosis for CD4+CD56+ malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells Blood, April 1, 2008; 111(7): 3778 - 3792. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020